Literature DB >> 12393649

Fas-mediated apoptosis is important in regulating cell replication and death in trisomy 8 hematopoietic cells but not in cells with other cytogenetic abnormalities.

Elaine M Sloand1, Sonnie Kim, Monika Fuhrer, Antonio M Risitano, Ryotaro Nakamura, Jaroslaw P Maciejewski, A John Barrett, Neal S Young.   

Abstract

Increased apoptosis of hematopoietic progenitor cells has been implicated in the pathophysiology of cytopenias associated with myelodysplastic syndromes (MDSs), and inhibition by immunosuppression may account for the success of this treatment in some patients. We examined bone marrow and peripheral blood of 25 patients with chromosomal abnormalities associated with MDS (monosomy 7, trisomy 8, and 5q-) for evidence of apoptosis. When fresh bone marrow was examined, the number of apoptotic and Fas-expressing CD34 cells was increased in patients with trisomy 8, but decreased in monosomy 7, as compared with healthy control donor marrow. Fas expression was increased in the trisomy 8 cells and decreased in the monosomy 7 cells when compared with normal cells from the same patient. Trisomy 8 cells were more likely to express activated caspase-3 than were normal cells. For bone marrow cells cultured with Fas agonist or Fas antagonist, the percentage of cells with trisomy 8 was significantly decreased in most cases after Fas receptor triggering and increased by Fas ligand (Fas-L) antagonist (P < 0.01), suggesting increased Fas susceptibility of cells with trisomy 8. No such changes were seen in cultures of cells with 5q- or monosomy 7. Fas antagonist facilitated the expansion of cells with trisomy 8 only. Cells with trisomy 8 appear to be more susceptible to Fas-mediated apoptosis. Clinical data demonstrating the responsiveness of some patients with trisomy 8 to anti-thymocyte globulin (ATG) and cyclosporine (CsA) would favor an active role of the immune system in this syndrome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393649     DOI: 10.1182/blood-2002-01-0096

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.

Authors:  Elaine M Sloand; A J Barrett
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

2.  Pediatric intestinal Behçet disease complicated by myeloid malignancies.

Authors:  Kiichiro Kanamitsu; Akira Shimada; Ritsuo Nishiuchi; Tomonari Shigemura; Yozo Nakazawa; Kenichi Koike; Yuichi Kodama; Yuichi Shinkoda; Yoshifumi Kawano; Kozo Yasui; Koji Sasaki; Ryosuke Kajiwara; Hirokazu Tsukahara; Atsushi Manabe
Journal:  Int J Hematol       Date:  2016-11-15       Impact factor: 2.490

Review 3.  Recent advances in understanding clonal haematopoiesis in aplastic anaemia.

Authors:  Natasha Stanley; Timothy S Olson; Daria V Babushok
Journal:  Br J Haematol       Date:  2017-01-20       Impact factor: 6.998

4.  Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor.

Authors:  Elaine M Sloand; Agnes S M Yong; Shakti Ramkissoon; Elena Solomou; Tullia C Bruno; Sonnie Kim; Monika Fuhrer; Sachiko Kajigaya; A John Barrett; Neal S Young
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-15       Impact factor: 11.205

5.  A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.

Authors:  Rami S Komrokji; Adam W Mailloux; Dung-Tsa Chen; Mikkael A Sekeres; Ronald Paquette; William J Fulp; Chiharu Sugimori; Jennifer Paleveda-Pena; Jaroslaw P Maciejewski; Alan F List; Pearlie K Epling-Burnette
Journal:  Haematologica       Date:  2014-01-31       Impact factor: 9.941

6.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study.

Authors:  Eva A Coenen; Susana C Raimondi; Jochen Harbott; Martin Zimmermann; Todd A Alonzo; Anne Auvrignon; H Berna Beverloo; Myron Chang; Ursula Creutzig; Michael N Dworzak; Erik Forestier; Brenda Gibson; Henrik Hasle; Christine J Harrison; Nyla A Heerema; Gertjan J L Kaspers; Anna Leszl; Nathalia Litvinko; Luca Lo Nigro; Akira Morimoto; Christine Perot; Dirk Reinhardt; Jeffrey E Rubnitz; Franklin O Smith; Jan Stary; Irina Stasevich; Sabine Strehl; Takashi Taga; Daisuke Tomizawa; David Webb; Zuzana Zemanova; Rob Pieters; C Michel Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Blood       Date:  2011-05-06       Impact factor: 22.113

7.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome.

Authors:  Elaine M Sloand; Lori Mainwaring; Monika Fuhrer; Shakti Ramkissoon; Antonio M Risitano; Keyvan Keyvanafar; Jun Lu; Atanu Basu; A John Barrett; Neal S Young
Journal:  Blood       Date:  2005-04-12       Impact factor: 22.113

Review 8.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

9.  Lymphocytes with aberrant expression of Fas or Fas ligand attenuate immune bone marrow failure in a mouse model.

Authors:  Stephanie O Omokaro; Marie J Desierto; Michael A Eckhaus; Felicia M Ellison; Jichun Chen; Neal S Young
Journal:  J Immunol       Date:  2009-03-15       Impact factor: 5.422

Review 10.  Apoptosis and antiapoptotic mechanisms in the progression of myelodysplastic syndrome.

Authors:  Daniella B Kerbauy; H Joachim Deeg
Journal:  Exp Hematol       Date:  2007-11       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.